drugset / Trial / NCT00241371
A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with clofarabine.
Timeline
- Start
- 2005-03
- Primary completion
- 2005-11
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clofarabine | Other / unclassified | 4 mg/m2 | Intravenous |